Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. NVDA
2. PSKY
3. META
4. LGND
5. SPY
6. MONC:IM
7. PTON
8. NYXH
9. LXEO
10. MONRY

Go back to Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
(NASDAQ: ELOX) Delayed: 16.54 -0.65 (3.78%)
Previous Close $17.19    52 Week High $ 
Open $17.01    52 Week Low $ 
Day High $17.01    P/E N/A 
Day Low $16.43    EPS $ 
Volume 3,562